Keywords
heart failure
chronic kidney disease
dialysis
myocardial revascularization
How to Cite
Abstract
Background: Cardiorenal syndrome is a pathology caused by dysfunction in the interdependence of these organs due to bidirectional interactions (acute or chronic), which can affect either renal or ventricular function.
Purpose: To present and justify chronic kidney disease as a trigger of congestive conditions due to de novo heart failure.
Case presentation: We report the case of a 69-year-old male patient percutaneously revascularized 3 years ago with multiple comorbidities who was admitted in the context of de novo heart failure secondary to his stage V chronic kidney disease on hemodialysis, in whom acute coronary artery disease and infiltrative cardiomyopathy were ruled out. The renal and cardiac injury was stabilized and the patient was discharged and continued outpatient management of his pathologies with adequate control of the same with nephrology and cardiology.
Discussion and conclusion: Cardiovascular disease generated by renal history has great repercussion in left ventricular function causing hypertrophy that leads to congestion with subsequent overload due to the fall of glomerular filtration resulting in a decrease of the ejection fraction.
Chronic kidney disease predisposes to alterations in cardiac function increasing cardiovascular risk.
References
Junho CV, Trentin-Sonoda M, Panico K, Dos Santos RS, Abrahão MV, Vernier IC, et al. Cardiorenal syndrome: long road between kidney and heart. Heart Fail Rev. 2022;27:2137-53. http://dx.doi.org/10.1007/s10741-022-10218-w
Chávez-Iñiguez JS, Sánchez-Villaseca SJ, García-Macías LA. Síndrome cardiorrenal: clasificación, fisiopatología, diagnóstico y tratamiento. Una revisión de las publicaciones médicas. Arch1 Cardiol Mex. 2022;92(2):253-63. http://dx.doi.org/10.24875/ACM.20000183
Dumler F. Síndrome Cardio-Renal: Revisión Mecanística. Diagnóstico. 2022;61(2):e364. https://doi.org/10.33734/diagnostico.v61i2.364
Thierer J. Síndrome cardiorrenal. Una revisión. Rev Urug Cardiol. 2018;33(1):81-133.
Alprecht-Quiroz P, Zúñiga-Pineda B, Lara-Terán JJ, Cáceres-Vinueza SV, Duarte-Vera YC. Síndrome cardiorrenal: aspectos clínicos y ecocardiográficos. Arch Cardiol Mex. 2020;90(4):503-10. https://doi.org/10.24875/ACM.20000087
House A, Wanner C, Sarna M, Piña I, McIntyre C, Komenda P, et al. Insuficiencia cardíaca en la enfermedad renal crónica: Conclusiones de Conferencia de Controversia de KDIGO (Kidney Disease Improving Global Outcomes). Kidney Int. 2019;95:1304-17. https://doi.org/10.1016/j.kint.2019.02.022
Mohamed RM, Elshazly SM, Nafea OE, Abd El Motteleb DM. Comparative cardioprotective effects of carvedilol versus atenolol in a rat model of cardiorenal syndrome type 4. Naunyn Schmiedebergs Arch Pharmacol. 2021;394(10):2117-28. http://dx.doi.org/10.1007/s00210-021-02130-1
Quiroga B, Santamaría Olomo R, Gorostidi M. Síndrome Cardiorrenal. Nefrología al día. 2023. https://www.nefrologiaaldia.org/555
Yogasundaram H, Chappell MC, Braam B, Oudit GY. Cardiorenal syndrome and heart failure-challenges and opportunities. Can J Cardiol. 2019;35(9):1208-19. http://dx.doi.org/10.1016/j.cjca.2019.04.002
Zhao LM, Lopes JL, Lopes CT, Santos VB, Barros AL. Factors associated with cardiorenal syndrome in patients with decompensated heart failure. Acta Paul Enferm. 2021;34:eAPE03193.
López Romero J, Ramos Cárdenas El, Vega Calderón F, Fariñas Peláez R, Viera Perez I. Enfermedad renal crónica oculta en pacientes con síndrome coronario agudo. Medicentro Electrón. 2020 mzo.;24(1):85-105. http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30432020000100085&lng=es
Giugliano D, Longo M, Signoriello S, Maiorino MI, Solerte B, Chiodini P, et al. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Cardiovasc Diabetol. 2022;21(1):42. http://dx.doi.org/10.1186/s12933-022-01474-z
Arce-Zepeda A, Ortiz-Espinoza L, Bernal-Amaral J, Badillo-Ramos I, Ahued-Vázquez S. Probabilidad de falla cardiaca aguda en enfermedad renal crónica. Rev Méd Inst Mexicano Seguro Social. 2021;59(4):322-9. https://docs.bvsalud.org/biblioref/2022/02/1359029/4060-26932-1-pb.pdf
Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American heart association. Circulation. 2019;139(16):e840-78. http://dx.doi.org/10.1161/CIR.0000000000000664
Tabucanon T, Tang WH. Right heart failure and cardiorenal syndrome. Cardiol Clin. 2020;38(2):185-202. http://dx.doi.org/10.1016/j.ccl.2020.01.004
Arends DM. Síndrome renocardiaco: de la disfunción renal a la disfunción cardíaca. Av Cardiol. 2018;38:39-44.
Calvo E, Cardona J, Cipolletti N, Volpi F, Álvarez Correa M, Orquera D, et al. Prevalencia e implicancias pronósticas del síndrome cardiorrenal en insuficiencia cardíaca aguda. Conarec. 2019;34(149):99-103. http://revistaconarec.com.ar/contenido/art.php?recordID=MTU4NQ==
Rozo- Ortiz EJ, Vargas LJ, Bautista-Moreno DG, Ortega-García SM, Valencia-Rincón LG, Hernández-Blanco LZ, et al. Síndrome cardiorrenal: enfoque diagnóstico, terapéutico y pronóstico. Med Int Méx. 2021;37(6):971-81. https://doi.org/10.24245/mim.v37i6.3562
Urbay Ruiz A, Gutierrez Perez E, Molina Linares I, Gonzalez Alvarez Y. Síndrome cardiorrenal: diagnóstico y tratamiento. Medicentro Electrón. 2023;27(4). https://medicentro.sld.cu/index.php/medicentro/article/view/3759
Costanzo MR. The cardiorenal syndrome in heart failure. Heart Fail Clin. 2020;16(1):81-97. http://dx.doi.org/10.1016/j.hfc.2019.08.010
Quijije Scott JM, Scott Álava MM, Quijije Scott BA. Alteraciones cardiovasculares en la enfermedad renal crónica. Reciamuc. 2023;7(2):2-9. https://doi.org/10.26820/reciamuc/7.(2).abril.2023.2-9
Pardo FJ. Síndrome cardiorrenal y metabólico y su relación con Atención Primaria. Diabetes Práct. 2023;14:11-4. https://diabetespractica.com/articulo/678
Pinheiro da Silva AL, Vaz da Silva MJ. Type 4 cardiorenal syndrome. Rev Port Cardiol. 2016;35(11):601-16. http://dx.doi.org/10.1016/j.repc.2016.06.007
Rodríguez Weber FL, Díaz Greene EJ, Cabrera Palos D. Miocardiopatía por amiloidosis. Acta Méd Grupo Ángeles. 2021;19(2):244-52. http://dx.doi.org/10.35366/100449
Manzur Barbur M, Mejía Sanjuanelo A, Anaya Taboada M, García Dominguez J, Molano Triviño A. Estado del arte del síndrome cardiorrenal, ventajas y limitaciones de las terapias conocidas. Rev Colomb Nefrol. 2021;8(2). http://dx.doi.org/10.22265/acnef.8.2.517
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.